Organization
Anhui Zhifei Longcom Biologic Pharmacy
24 clinical trials
1 abstract
Clinical trial
Phase I Clinical Trial to Evaluate the Safety and Tolerability of BCG for Therapeutic Use in Preventing Postoperative Recurrence of Non-muscular Invasive Bladder Cancer in People Aged 18 and OverStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Blind, Position-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Quadrivalent Influenza Virus Split Vaccine in 6-35 Months of AgeStatus: Completed, Estimated PCD: 2024-01-05
Clinical trial
Randomized, Blind, Phase III Clinical Trial Comparing the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (MRC-5 Cells) With a 5-dose Program and a 4-dose (2-dose First-dose) ProgramStatus: Completed, Estimated PCD: 2021-07-21
Clinical trial
A Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and AboveStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Above.Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Open, Positive Controlled Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) in People Aged 18 Years and OverStatus: Completed, Estimated PCD: 2022-10-09
Clinical trial
Study on the Immunogenicity and Safety of Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Inoculation With Two Doses of Inactivated Vaccine (CoronaVac) in People Over 18 Years OldStatus: Completed, Estimated PCD: 2022-06-03
Clinical trial
Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of BCG Vaccine for Intradermal Injection in 6-65 Year OldsStatus: Completed, Estimated PCD: 2022-10-30
Clinical trial
Anhui Zhifei Longcom Biologic Pharmacy co. Ltd.Status: Recruiting, Estimated PCD: 2023-07-30
Clinical trial
To Evaluate the Immunogenicity and Safety of Sequentially Enhanced Recombinant Novel Coronavirus Vaccine (CHO Cells) in Patients Aged 3-17 Years After Completion of Two Doses of Novel Coronavirus Inactivated VaccineStatus: Completed, Estimated PCD: 2022-11-19
Clinical trial
Multi-center Safety Observation of COVID19 Vaccine in a Large PopulationStatus: Recruiting, Estimated PCD: 2022-06-16
Clinical trial
To Evaluate the Immunogenicity and Safety of Booster Immunization 12 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-07-19
Clinical trial
A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of AgeStatus: Completed, Estimated PCD: 2021-12-12
Clinical trial
To Evaluate the Immunogenicity and Safety of Booster Immunization 6 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People 18 Years of Age and OlderStatus: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.Status: Completed, Estimated PCD: 2022-02-14
Clinical trial
Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and OlderStatus: Active (not recruiting), Estimated PCD: 2024-02-02
Clinical trial
A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Older With Different Immunization ProgramsStatus: Not yet recruiting, Estimated PCD: 2024-05-15
Clinical trial
Randomized, Blinded, Single-arm Intradermal Injection, Control of Similar Products on the Market, the Safety Pre-evaluation Phase I Clinical Trial of BCG-PPD in Tuberculosis PatientsStatus: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirus（COVID-19）Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and OverStatus: Completed, Estimated PCD: 2022-03-04
Clinical trial
Phase IV Clinical Trial of the Safety, Efficacy, and Immunogenicity of Mycobacterium Vaccae for Injection (Mica) in People Over 15 Years of Age With Latent Mycobacterium Tuberculosis InfectionStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized, Blinded, and Similar Vaccine-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of the 5-dose Program and 4-dose (2-1-1) Program of Freeze-dried Human Rabies Vaccine (Vero Cells)Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
To Conduct a Phase IV Clinical Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population Aged 6 Months and Above.Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase Ⅱ Study on the Safety, Tolerability and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-driedStatus: , Estimated PCD: 2024-06-30
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,